Q3 EPS Forecast for Century Therapeutics Reduced by Analyst

Century Therapeutics, Inc. (NASDAQ:IPSC) – Analysts at HC Wainwright decreased their Q3 2026 earnings estimates for Century Therapeutics in a research note issued on Thursday, August 13th. HC Wainwright analyst M. Kapoor now anticipates that the company will post earnings per share of ($0.12) for the quarter, down from their prior forecast of ($0.11). HC Wainwright has a “Buy” rating and a $5.00 price objective on the stock. The consensus estimate for Century Therapeutics’ current full-year earnings is ($0.47) per share. HC Wainwright also issued estimates for Century Therapeutics’ FY2026 earnings at ($0.51) EPS, Q3 2027 earnings at ($0.12) EPS, Q4 2027 earnings at ($0.12) EPS and FY2027 earnings at ($0.47) EPS.

A number of other equities analysts have also recently commented on the company. Mizuho assumed coverage on Century Therapeutics in a report on Wednesday, May 27th. They set an “outperform” rating and a $8.00 price target for the company. Wall Street Zen lowered Century Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, June 27th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Century Therapeutics in a research report on Thursday, July 2nd. Four investment analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the company presently has an average rating of “Hold” and an average target price of $4.75.

Century Therapeutics Stock Performance

Shares of IPSC stock opened at $1.96 on Monday. Century Therapeutics has a 52-week low of $0.43 and a 52-week high of $3.04. The stock has a market cap of $353.49 million, a price-to-earnings ratio of -2.11 and a beta of 1.57. The firm’s 50-day moving average is $2.18 and its 200-day moving average is $2.21.

Century Therapeutics (NASDAQ:IPSC) last announced its quarterly earnings data on Wednesday, August 12th. The company reported ($0.17) EPS for the quarter, missing analysts’ consensus estimates of ($0.11) by ($0.06).

Hedge Funds Weigh In On Century Therapeutics

Institutional investors and hedge funds have recently made changes to their positions in the company. Versant Venture Management LLC bought a new position in shares of Century Therapeutics during the first quarter worth approximately $27,495,000. Commodore Capital LP bought a new stake in Century Therapeutics in the 1st quarter valued at $19,652,000. BlackRock Inc. bought a new stake in Century Therapeutics in the 2nd quarter valued at $19,825,000. Seven Fleet Capital Management LP acquired a new position in Century Therapeutics in the 1st quarter valued at $9,826,000. Finally, Trails Edge Capital Partners LP acquired a new position in Century Therapeutics in the 2nd quarter valued at $10,130,674,000. Institutional investors and hedge funds own 50.20% of the company’s stock.

Century Therapeutics Company Profile

Century Therapeutics is a clinical-stage biotechnology company focused on the discovery and development of allogeneic cell therapies for cancer. Utilizing induced pluripotent stem cell (iPSC) technology, the company engineers “off-the-shelf” natural killer (NK) and T cell candidates designed to target hematologic malignancies and solid tumors. By harnessing iPSC-derived immune cells, Century aims to overcome challenges associated with patient-derived therapies, such as manufacturing variability and treatment delays.

The company’s proprietary platform integrates gene editing, synthetic biology and scalable cell expansion processes to generate a pipeline of product candidates.